Asthma Forecast and Market Analysis to 2024

Table of Contents

1 TABLE OF CONTENTS (Forecast, Treatment, Epidemiology and Pipeline Datapacks included)

• FORECAST: ASTHMA IN THE US, JAPAN, AND 5EU (Published on 16 February 2018)


• EXECUTIVE SUMMARY


• RECENT FORECAST UPDATES


• MARKET DYNAMICS


• FORECAST AND FUTURE TRENDS


• MARKET DEFINITION AND METHODOLOGY


• PRIMARY RESEARCH METHODOLOGY


• BIBLIOGRAPHY


• PRODUCT PROFILE: ADVAIR


• PRODUCT PROFILE: BREO ELLIPTA


• PRODUCT PROFILE: CINQAIR


• PRODUCT PROFILE: DULERA


• PRODUCT PROFILE (LATE STAGE): DUPIXENT


• PRODUCT PROFILE: FASENRA


• PRODUCT PROFILE: FLUTIFORM


• PRODUCT PROFILE: NUCALA


• PRODUCT PROFILE (LATE STAGE): QVM149


• PRODUCT PROFILE: SINGULAIR


• PRODUCT PROFILE: SPIRIVA


• PRODUCT PROFILE: SYMBICORT


• PRODUCT PROFILE (LATE STAGE): TRELEGY ELLIPTA


• PRODUCT PROFILE: XOLAIR

2 TREATMENT: ASTHMA (Published on 19 February 2018)

• EXECUTIVE SUMMARY


• PRIMARY RESEARCH METHODOLOGY


• DISEASE DEFINITION AND DIAGNOSIS


• PATIENT SEGMENTATION


• COUNTRY TREATMENT TREES


• CURRENT TREATMENT OPTIONS


• PRESCRIBING TRENDS


• IMPACT OF GENERICS


• UNMET NEEDS IN ASTHMA

3 EPIDEMIOLOGY: ASTHMA (Published on 05 January 2018)

• EXECUTIVE SUMMARY


• DISEASE BACKGROUND


• METHODOLOGY


• FORECAST


• EPIDEMIOLOGIST INSIGHT


• STRENGTHS AND LIMITATIONS


• BIBLIOGRAPHY


• APPENDIX: ADDITIONAL SOURCES

4 MARKETED DRUGS: ASTHMA (Published on 16 February 2018)

• EXECUTIVE SUMMARY


• PRODUCT OVERVIEW


• PRODUCT PROFILE: ADVAIR


• PRODUCT PROFILE: BREO ELLIPTA


• PRODUCT PROFILE: CINQAIR


• PRODUCT PROFILE: DULERA


• PRODUCT PROFILE: FASENRA


• PRODUCT PROFILE: FLUTIFORM


• PRODUCT PROFILE: NUCALA


• PRODUCT PROFILE: SINGULAIR


• PRODUCT PROFILE: SPIRIVA


• PRODUCT PROFILE: SYMBICORT


• PRODUCT PROFILE: XOLAIR

5 ASTHMA PRICING, REIMBURSEMENT, AND ACCESS (Published on 05 May 2016)

• EXECUTIVE SUMMARY


• MARKET CONTEXT


• GLOBAL PAYER INSIGHTS


• US PRICING


• US PAYER INSIGHTS


• US REIMBURSEMENT


• JAPAN


• FIVE MAJOR EU MARKETS PRICING


• FIVE MAJOR EU MARKETS PAYER INSIGHTS


• GENERIC ICS/LABA INHALERS IN THE FIVE MAJOR EU MARKETS


• FRANCE


• GERMANY


• ITALY


• SPAIN


• UK


• METHODOLOGY

6 PIPELINE: ASTHMA (Published on 16 February 2018)

• EXECUTIVE SUMMARY


• CLINICAL PIPELINE OVERVIEW


• PRODUCT PROFILE (LATE STAGE): DUPIXENT


• PRODUCT PROFILE (LATE STAGE): QVM149


• PRODUCT PROFILE (LATE STAGE): TRELEGY ELLIPTA

List of Figures
Figure 1: Asthma - current and future market dynamics analysis
Figure 2: The author’s assessment summary of key marketed and pipeline drugs for asthma
Figure 3: Asthma sales across the US, Japan, and five major EU markets, by country, 2017-26
Figure 4: Asthma sales across the US, Japan, and five major EU markets, by class, 2017-26
Figure 5: Sales of IL inhibitors across the US, Japan, and five major EU markets, by drug, 2017-26
Figure 6: Sales of ICS/LABA therapies across the US, Japan, and five major EU markets, by drug, 2017-26
Figure 7: Triple therapy sales across the US, Japan, and five major EU markets, by drug, 2017-26
Figure 8: Patient-based asthma forecast methodology
Figure 9: Price sources and calculations, by country
Figure 10: Advair for asthma - SWOT analysis
Figure 11: The author’s drug assessment summary of Advair in asthma
Figure 12: The author’s drug assessment summary of Advair in asthma
Figure 13: Advair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 14: Breo Ellipta for asthma - SWOT analysis
Figure 15: The author’s drug assessment summary of Breo Ellipta in asthma
Figure 16: The author’s drug assessment summary of Breo Ellipta in asthma
Figure 17: Breo Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 18: Cinqair for asthma - SWOT analysis
Figure 19: The author’s drug assessment summary of Cinqair in asthma
Figure 20: The author’s drug assessment summary of Cinqair in asthma
Figure 21: Cinqair sales for asthma across the US and five major EU markets, by country, 2017-26
Figure 22: Dulera for asthma - SWOT analysis
Figure 23: The author’s drug assessment summary of Dulera in asthma
Figure 24: The author’s drug assessment summary of Dulera in asthma
Figure 25: Dulera sales for asthma in the US, 2017-26
Figure 26: Dupixent for asthma - SWOT analysis
Figure 27: The author’s drug assessment summary of Dupixent in asthma
Figure 28: The author’s drug assessment summary of Dupixent in asthma
Figure 29: Dupixent sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 30: Fasenra for asthma - SWOT analysis
Figure 31: The author’s drug assessment summary of Fasenra in asthma
Figure 32: The author’s drug assessment summary of Fasenra in asthma
Figure 33: Fasenra sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 34: Flutiform for asthma - SWOT analysis
Figure 35: The author’s drug assessment summary of Flutiform in asthma
Figure 36: The author’s drug assessment summary of Flutiform in asthma
Figure 37: Flutiform sales for asthma across Japan and the five major EU markets, by country, 2017-26
Figure 38: Nucala for asthma - SWOT analysis
Figure 39: The author’s drug assessment summary of Nucala in asthma
Figure 40: The author’s drug assessment summary of Nucala in asthma
Figure 41: Nucala sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 42: QVM149 for asthma - SWOT analysis
Figure 43: The author’s drug assessment summary of QVM149 in asthma
Figure 44: The author’s drug assessment summary of QVM149 in asthma
Figure 45: QVM149 sales for asthma across Japan and the five major EU markets, by country, 2017-26
Figure 46: Singulair for asthma - SWOT analysis
Figure 47: The author’s drug assessment summary of Singulair in asthma
Figure 48: The author’s drug assessment summary of Singulair in asthma
Figure 49: Singulair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 50: Spiriva for asthma - SWOT analysis
Figure 51: The author’s drug assessment summary of Spiriva in asthma
Figure 52: The author’s drug assessment summary of Spiriva in asthma
Figure 53: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 54: Symbicort for asthma - SWOT analysis
Figure 55: The author’s drug assessment summary of Symbicort in asthma
Figure 56: The author’s drug assessment summary of Symbicort in asthma
Figure 57: Symbicort sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 58: Trelegy Ellipta for asthma - SWOT analysis
Figure 59: The author’s drug assessment summary of Trelegy Ellipta in asthma
Figure 60: The author’s drug assessment summary of Trelegy Ellipta in asthma
Figure 61: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 62: Xolair for asthma - SWOT analysis
Figure 63: The author’s drug assessment summary of Xolair in asthma
Figure 64: The author’s drug assessment summary of Xolair in asthma
Figure 65: Xolair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 66: Percentage of asthma patients remaining undiagnosed, by severity and country (%)
Figure 67: Severity of diagnosed asthma patients in the US, Japan, and five major EU markets, by country (%), 2017
Figure 68: Trend in 12-month diagnosed prevalent cases of asthma in the US, Japan, and five major EU markets, by country, 2016-36
Figure 69: Absolute change in 12-month diagnosed prevalent cases of asthma in the US, Japan, and five major EU markets, by country, 2016-36
Figure 70: Advair for asthma - SWOT analysis
Figure 71: The author’s drug assessment summary of Advair in asthma
Figure 72: The author’s drug assessment summary of Advair in asthma
Figure 73: Advair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 74: Breo Ellipta for asthma - SWOT analysis
Figure 75: The author’s drug assessment summary of Breo Ellipta in asthma
Figure 76: The author’s drug assessment summary of Breo Ellipta in asthma
Figure 77: Breo Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 78: Cinqair for asthma - SWOT analysis
Figure 79: The author’s drug assessment summary of Cinqair in asthma
Figure 80: The author’s drug assessment summary of Cinqair in asthma
Figure 81: Cinqair sales for asthma across the US and five major EU markets, by country, 2017-26
Figure 82: Dulera for asthma - SWOT analysis
Figure 83: The author’s drug assessment summary of Dulera in asthma
Figure 84: The author’s drug assessment summary of Dulera in asthma
Figure 85: Dulera sales for asthma in the US, 2017-26
Figure 86: Fasenra for asthma - SWOT analysis
Figure 87: The author’s drug assessment summary of Fasenra in asthma
Figure 88: The author’s drug assessment summary of Fasenra in asthma
Figure 89: Fasenra sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 90: Flutiform for asthma - SWOT analysis
Figure 91: The author’s drug assessment summary of Flutiform in asthma
Figure 92: The author’s drug assessment summary of Flutiform in asthma
Figure 93: Flutiform sales for asthma across Japan and the five major EU markets, by country, 2017-26
Figure 94: Nucala for asthma - SWOT analysis
Figure 95: The author’s drug assessment summary of Nucala in asthma
Figure 96: The author’s drug assessment summary of Nucala in asthma
Figure 97: Nucala sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 98: Singulair for asthma - SWOT analysis
Figure 99: The author’s drug assessment summary of Singulair in asthma
Figure 100: The author’s drug assessment summary of Singulair in asthma
Figure 101: Singulair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 102: Spiriva for asthma - SWOT analysis
Figure 103: The author’s drug assessment summary of Spiriva in asthma
Figure 104: The author’s drug assessment summary of Spiriva in asthma
Figure 105: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 106: Symbicort for asthma - SWOT analysis
Figure 107: The author’s drug assessment summary of Symbicort in asthma
Figure 108: The author’s drug assessment summary of Symbicort in asthma
Figure 109: Symbicort sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 110: Xolair for asthma - SWOT analysis
Figure 111: The author’s drug assessment summary of Xolair in asthma
Figure 112: The author’s drug assessment summary of Xolair in asthma
Figure 113: Xolair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 114: Dupixent for asthma - SWOT analysis
Figure 115: The author’s drug assessment summary of Dupixent in asthma
Figure 116: The author’s drug assessment summary of Dupixent in asthma
Figure 117: Dupixent sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 118: QVM149 for asthma - SWOT analysis
Figure 119: The author’s drug assessment summary of QVM149 in asthma
Figure 120: The author’s drug assessment summary of QVM149 in asthma
Figure 121: QVM149 sales for asthma across Japan and the five major EU markets, by country, 2017-26
Figure 122: Trelegy Ellipta for asthma - SWOT analysis
Figure 123: The author’s drug assessment summary of Trelegy Ellipta in asthma
Figure 124: The author’s drug assessment summary of Trelegy Ellipta in asthma
Figure 125: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: Exchange rates used for calculating prices
Table 2: Primary care physicians and pulmonologists surveyed for the asthma primary research study, 2017
Table 3: Advair drug profile
Table 4: Advair Diskus pivotal trial data in asthma
Table 5: Advair HFA pivotal trial data in asthma
Table 6: Advair late-phase trial data in asthma
Table 7: Advair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 8: Breo Ellipta drug profile
Table 9: Breo Ellipta pivotal trial data in asthma
Table 10: Breo Ellipta late-phase trial data in asthma
Table 11: Breo Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 12: Cinqair drug profile
Table 13: Cinqair pivotal Phase III data in asthma
Table 14: Cinqair sales for asthma across the US and five major EU markets, by country ($m), 2017-26
Table 15: Dulera drug profile
Table 16: Dulera pivotal trial data in asthma
Table 17: Dulera Phase IV trial in asthma
Table 18: Dulera sales for asthma in the US ($m), 2017-26
Table 19: Dupixent drug profile
Table 20: Dupixent Phase III data in asthma
Table 21: Dupixent Phase III trials in asthma
Table 22: Dupixent sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 23: Fasenra drug profile
Table 24: Fasenra Phase III trials in asthma
Table 25: Ongoing Phase III trials for Fasenra in asthma
Table 26: Fasenra sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 27: Flutiform drug profile
Table 28: Flutiform pivotal trial data in asthma
Table 29: Flutiform Phase III trials in asthma
Table 30: Flutiform sales for asthma across Japan and the five major EU markets, by country ($m), 2017-26
Table 31: Nucala drug profile
Table 32: Nucala pivotal trial data in asthma
Table 33: Nucala late-phase trial data in asthma
Table 34: Nucala Phase III trials in asthma
Table 35: Nucala sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 36: QVM149 drug profile
Table 37: QVM149 Phase III trials in asthma
Table 38: QVM149 sales for asthma across Japan and the five major EU markets, by country ($m), 2017-26
Table 39: Singulair drug profile
Table 40: Singulair pivotal trial data in asthma
Table 41: Singulair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 42: Spiriva drug profile
Table 43: Spiriva pivotal trial data in asthma
Table 44: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 45: Symbicort drug profile
Table 46: Symbicort pivotal trial data in asthma
Table 47: Symbicort late-phase trial data in asthma
Table 48: Symbicort sales for asthma in the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 49: Trelegy Ellipta drug profile
Table 50: Trelegy Ellipta Phase III trials in asthma
Table 51: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 52: Xolair drug profile
Table 53: Xolair pivotal trial data in asthma
Table 54: Xolair late-phase trial data in asthma
Table 55: Xolair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 56: Physicians surveyed for the asthma primary research study, 2017
Table 57: ICD-10 codes associated with asthma
Table 58: Classification of asthma in patients aged =12 years who are not taking long-term control medications, by impairment and risk
Table 59: Classification of patients after asthma becomes well controlled, by lowest level of treatment required to maintain control
Table 60: Severity of diagnosed asthma patients in the US, Japan, and five major EU markets, by country (%), 2017
Table 61: Branded therapies available for asthma across the US, Japan, and five major EU markets
Table 62: Global Initiative for Asthma stepwise approach for adjusting treatment of asthma
Table 63: Percentage of respondents using each set of guidelines for treatment of asthma, by country (%)
Table 64: Management of asthma patients in the US, Japan, and five major EU markets, by country, disease severity, and type of healthcare professional (%)
Table 65: Percentage of patients lost to follow-up*, by severity and country (%)
Table 66: Proportion of annual prescriptions filled, by severity and country (%)
Table 67: Prescribing influences in the treatment of asthma in the US, Japan, and five major EU markets, by country (%)
Table 68: Expected patient switching to inhaled generics in the US, Japan, and five major EU markets, by device type (%)
Table 69: Treatment challenges in asthma
Table 70: Patient compliance with asthma treatments, by drug formulation and country (%)
Table 71: Sources used for the epidemiological analysis of diagnosed asthma in the US, Japan, and five major EU markets, by country
Table 72: Global Initiative for Asthma guidelines on severity
Table 73: 12-month diagnosed prevalent cases of asthma in the US, Japan, and five major EU markets, by country, 2016-36
Table 74: Age- and gender-specific 12-month diagnosed prevalent cases of asthma in the US, Japan, and five major EU markets, by country, 2016
Table 75: 12-month prevalent cases of asthma in the US, Japan, and five major EU markets, by severity and country, 2016
Table 76: Validation of asthma prevalence forecast estimates against benchmark estimates
Table 77: Profiled key marketed drugs for asthma
Table 78: Advair drug profile
Table 79: Advair Diskus pivotal trial data in asthma
Table 80: Advair HFA pivotal trial data in asthma
Table 81: Advair late-phase trial data in asthma
Table 82: Advair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 83: Breo Ellipta drug profile
Table 84: Breo Ellipta pivotal trial data in asthma
Table 85: Breo Ellipta late-phase trial data in asthma
Table 86: Breo Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 87: Cinqair drug profile
Table 88: Cinqair pivotal Phase III data in asthma
Table 89: Cinqair sales for asthma across the US and five major EU markets, by country ($m), 2017-26
Table 90: Dulera drug profile
Table 91: Dulera pivotal trial data in asthma
Table 92: Dulera Phase IV trial in asthma
Table 93: Dulera sales for asthma in the US ($m), 2017-26
Table 94: Fasenra drug profile
Table 95: Fasenra Phase III trials in asthma
Table 96: Ongoing Phase III trials for Fasenra in asthma
Table 97: Fasenra sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 98: Flutiform drug profile
Table 99: Flutiform pivotal trial data in asthma
Table 100: Flutiform Phase III trials in asthma
Table 101: Flutiform sales for asthma across Japan and the five major EU markets, by country ($m), 2017-26
Table 102: Nucala drug profile
Table 103: Nucala pivotal trial data in asthma
Table 104: Nucala late-phase trial data in asthma
Table 105: Nucala Phase III trials in asthma
Table 106: Nucala sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 107: Singulair drug profile
Table 108: Singulair pivotal trial data in asthma
Table 109: Singulair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 110: Spiriva drug profile
Table 111: Spiriva pivotal trial data in asthma
Table 112: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 113: Symbicort drug profile
Table 114: Symbicort pivotal trial data in asthma
Table 115: Symbicort late-phase trial data in asthma
Table 116: Symbicort sales for asthma in the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 117: Xolair drug profile
Table 118: Xolair pivotal trial data in asthma
Table 119: Xolair late-phase trial data in asthma
Table 120: Xolair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 121: Marketed products and approved indications for asthma in the US, Japan, and five major EU markets
Table 122: Pivotal safety and efficacy clinical trials for late-stage pipeline candidates in asthma
Table 123: US pricing of key marketed drugs
Table 124: Asthma and chronic obstructive pulmonary disease spend by payers, 2014
Table 125: Top 10 asthma and chronic obstructive pulmonary disease drug spend by Express Scripts members
Table 126: Spend on the top three asthma and chronic obstructive pulmonary disease drugs by Medicare Part D beneficiaries, 2013
Table 127: Global Initiative for Asthma treatment guidelines
Table 128: Formulary placement of asthma drugs in selected commercial formularies
Table 129: Formulary placement of asthma drugs in the top five 2016 Medicare Part D formularies
Table 130: Formulary placement of asthma drugs in selected large Medicaid states’ preferred drug lists
Table 131: CVS Caremark’s and Express Scripts’ formulary-excluded asthma drugs
Table 132: Express Scripts’ TRICARE formulary placement of asthma drugs
Table 133: Prior authorization criteria for asthma drugs by major health insurers and pharmacy benefit managers
Table 134: Pricing premiums given to medicines that can demonstrate benefit over comparators
Table 135: Pricing of key marketed asthma drugs in Japan
Table 136: Price calculation methodologies for asthma drugs launched in Japan after 2008
Table 137: Annual treatment cost of asthma drugs in the five major EU markets
Table 138: Access controls for asthma medications in the five major EU markets
Table 139: Availability and substitutability of branded generic inhalers in the five major EU markets
Table 140: List price differential between branded ICS/LABAs and branded generics in the five major EU markets
Table 141: Market access levers impacting ICS/LABA generic inhaler uptake in the five major EU markets
Table 142: Transparency Committee’s ASMR ratings and pricing implications
Table 143: Transparency Committee’s SMR ratings and pricing implications
Table 144: Transparency Committee’s assessment of asthma treatments
Table 145: G-BA assessment of key asthma therapy
Table 146: Reimbursement conditions for asthma treatments in Italy
Table 147: Local formulary decisions for asthma drugs
Table 148: Therapeutic positioning reports for asthma drugs in Spain
Table 149: Spain regional assessments of asthma drugs
Table 150: NICE assessments of key asthma therapies
Table 151: CCG formulary inclusions for key asthma drugs
Table 152: SMC decisions on key asthma therapies
Table 153: SIGN asthma treatment guidelines
Table 154: Price sources and calculations for the US
Table 155: Price sources and calculations for the EU
Table 156: Exchange rates used for calculating branded drug prices
Table 157: Late-phase pipeline products in development for asthma
Table 158: Dupixent drug profile
Table 159: Dupixent Phase III data in asthma
Table 160: Dupixent Phase III trials in asthma
Table 161: Dupixent sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 162: QVM149 drug profile
Table 163: QVM149 Phase III trials in asthma
Table 164: QVM149 sales for asthma across Japan and the five major EU markets, by country ($m), 2017-26
Table 165: Trelegy Ellipta drug profile
Table 166: Trelegy Ellipta Phase III trials in asthma
Table 167: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26